{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:57:21Z","timestamp":1793656641468,"version":"4.5.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>\n                    Primary hyperaldosteronism is a common cause of resistant hypertension. Aldosterone is produced in the adrenal by aldosterone synthase (AS, encoded by the gene CYP11B2). AS shares 93% homology to 11\u03b2-hydroxylase (encoded by the gene CYP11B1), responsible for cortisol production. This homology has hitherto impeded the development of a drug, which selectively suppresses aldosterone but not cortisol production, as a new treatment for primary hyperaldosteronism. We now report the development of RO6836191 as a potent (Ki 13 nmol\/L) competitive inhibitor of AS, with in vitro selectivity &gt;100-fold over 11\u03b2-hydroxylase. In cynomolgus monkeys challenged with synthetic adrenocorticotropic hormone, single doses of RO6836191 inhibited aldosterone synthesis without affecting the adrenocorticotropic hormone\u2013induced rise in cortisol. In repeat-dose toxicity studies in monkeys, RO6836191 reproduced the adrenal changes of the AS\n                    <jats:sup>\u2212<\/jats:sup>\n                    <jats:sup>\/\u2212<\/jats:sup>\n                    mouse: expansion of the zona glomerulosa; increased expression of AS (or disrupted green fluorescent protein gene in the AS\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mouse); hypertrophy, proliferation, and apoptosis of zona glomerulosa cells. These changes in the monkey were partially reversible and partially preventable by electrolyte supplementation and treatment with an angiotensin-converting enzyme inhibitor. In healthy subjects, single doses of RO6836191, across a 360-fold dose range, reduced plasma and urine aldosterone levels with maximum suppression at a dose of 10 mg, but unchanged cortisol, on adrenocorticotropic hormone challenge, up to 360 mg, and increase in the precursors 11-deoxycorticosterone and 11-deoxycortisol only at or &gt;90 mg. In conclusion, RO6836191 demonstrates that it is possible to suppress aldosterone production completely in humans without affecting cortisol production.\n                  <\/jats:p>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration\u2014<\/jats:title>\n                    <jats:p>\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      . Unique identifier: NCT01995383.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/hypertensionaha.116.07716","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T22:50:23Z","timestamp":1479768623000},"page":"189-196","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":116,"title":["Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2)"],"prefix":"10.1161","volume":"69","author":[{"given":"Katrijn","family":"Bogman","sequence":"first","affiliation":[{"name":"From the Clinical Pharmacology (K.B., D.S., M.-L.D.), Biostatistics (G.P.), Discovery (K.A.), Pharmaceutical Sciences (S.M., M.C.D.V.M.), and Translational Medicine, Cardiovascular Diseases (P.F.), Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland; and Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, United Kingdom (M.J.B)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Schwab","sequence":"additional","affiliation":[{"name":"From the Clinical Pharmacology (K.B., D.S., M.-L.D.), Biostatistics (G.P.), Discovery (K.A.), Pharmaceutical Sciences (S.M., M.C.D.V.M.), and Translational Medicine, Cardiovascular Diseases (P.F.), Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland; and Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, United Kingdom (M.J.B)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Delporte","sequence":"additional","affiliation":[{"name":"From the Clinical Pharmacology (K.B., D.S., M.-L.D.), Biostatistics (G.P.), Discovery (K.A.), Pharmaceutical Sciences (S.M., M.C.D.V.M.), and Translational Medicine, Cardiovascular Diseases (P.F.), Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland; and Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, United Kingdom (M.J.B)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palermo","sequence":"additional","affiliation":[{"name":"From the Clinical Pharmacology (K.B., D.S., M.-L.D.), Biostatistics (G.P.), Discovery (K.A.), Pharmaceutical Sciences (S.M., M.C.D.V.M.), and Translational Medicine, Cardiovascular Diseases (P.F.), Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland; and Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, United Kingdom (M.J.B)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Amrein","sequence":"additional","affiliation":[{"name":"From the Clinical Pharmacology (K.B., D.S., M.-L.D.), Biostatistics (G.P.), Discovery (K.A.), Pharmaceutical Sciences (S.M., M.C.D.V.M.), and Translational Medicine, Cardiovascular Diseases (P.F.), Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland; and Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, United Kingdom (M.J.B)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Mohr","sequence":"additional","affiliation":[{"name":"From the Clinical Pharmacology (K.B., D.S., M.-L.D.), Biostatistics (G.P.), Discovery (K.A.), Pharmaceutical Sciences (S.M., M.C.D.V.M.), and Translational Medicine, Cardiovascular Diseases (P.F.), Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland; and Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, United Kingdom (M.J.B)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"De Vera Mudry","sequence":"additional","affiliation":[{"name":"From the Clinical Pharmacology (K.B., D.S., M.-L.D.), Biostatistics (G.P.), Discovery (K.A.), Pharmaceutical Sciences (S.M., M.C.D.V.M.), and Translational Medicine, Cardiovascular Diseases (P.F.), Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland; and Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, United Kingdom (M.J.B)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris J.","family":"Brown","sequence":"additional","affiliation":[{"name":"From the Clinical Pharmacology (K.B., D.S., M.-L.D.), Biostatistics (G.P.), Discovery (K.A.), Pharmaceutical Sciences (S.M., M.C.D.V.M.), and Translational Medicine, Cardiovascular Diseases (P.F.), Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland; and Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, United Kingdom (M.J.B)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ferber","sequence":"additional","affiliation":[{"name":"From the Clinical Pharmacology (K.B., D.S., M.-L.D.), Biostatistics (G.P.), Discovery (K.A.), Pharmaceutical Sciences (S.M., M.C.D.V.M.), and Translational Medicine, Cardiovascular Diseases (P.F.), Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland; and Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, United Kingdom (M.J.B)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042711-135929"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000064344.00173.44"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.303587"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/2048004014522440"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00980.x"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.110"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs388"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2003.10.011"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)30030-4"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2011.07.034"},{"key":"e_1_3_4_12_2","volume-title":"Greenspan\u2019s Basic and Clinical Endocrinology","author":"Gardner DG","year":"2007","unstructured":"Gardner DG, Shoback D. Greenspan\u2019s Basic and Clinical Endocrinology. 8th. New York, NY: McGraw Hill Medical; 2007.","edition":"8"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(10)60584-0"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.157271"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.029892"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2012.00667.x"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12051"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328363570c"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2117"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2013.266"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00851"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026611313120003"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(98)00067-7"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01545"},{"key":"e_1_3_4_25_2","first-page":"477","article-title":"[Clinical evaluation of CGS16949A in advanced or recurrent breast cancer\u2014a multi-institutional late phase II clinical trial].","volume":"21","author":"Aoyama H","year":"1994","unstructured":"Aoyama H, Asaishi K, Abe R, Kajiwara T, Enomoto K, Yoshida M, Ohasi Y, Tominaga T, Abe O. [Clinical evaluation of CGS16949A in advanced or recurrent breast cancer\u2014a multi-institutional late phase II clinical trial]. Gan To Kagaku Ryoho. 1994;21:477\u2013484.","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_3_4_26_2","first-page":"485","article-title":"[Late phase II study of CGS16949A, a new aromatase inhibitor\u2014a multicentral cooperative study (Western Japan Group)].","volume":"21","author":"Wada T","year":"1994","unstructured":"Wada T, Nomura Y, Oohashi Y, Abe O, Koyama H, Takashima S. [Late phase II study of CGS16949A, a new aromatase inhibitor\u2014a multicentral cooperative study (Western Japan Group)]. Gan To Kagaku Ryoho. 1994;21:485\u2013493.","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-1102"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-180"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00129784-200505010-00007"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht187"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.16.9424"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.116.07716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:20:47Z","timestamp":1715577647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.116.07716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.116.07716"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.116.07716","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"2016-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}